JNJ vs SLB: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
VS
SLB N.V. · Energy
$51.92
-20.2% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
JNJ has more upside to fair value
(-11.8%).
SLB trades at a lower forward P/E
(18.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
SLB |
| Current Price |
$238.46 |
$51.92 |
| Fair Value Estimate |
$210.28 |
$41.43 |
| Upside to Fair Value |
-11.8%
|
-20.2%
|
| Market Cap |
$574.7B |
$77.9B |
| Forward P/E |
20.2x
|
18.6x
|
| EV / EBITDA |
13.3x
|
9.2x
|
| Price / Sales |
6.2x
|
2.2x
|
| Price / FCF |
29.4x
|
16.1x
|
| Revenue Growth YoY |
+6.1%
|
-1.6%
|
| Gross Margin |
72.8%
|
18.21%
|
| Operating Margin |
27.2%
|
15.28%
|
| Return on Equity |
32.87%
|
12.83%
|
| Dividend Yield |
2.18% |
2.21% |
| FCF Yield |
3.4%
|
6.21%
|
| Analyst Consensus |
Moderate Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
SLB is the world's largest oilfield services company with $35.7B in FY2025 revenue, operating across four divisions: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems. The company completed the ChampionX acquisition in 2025 and is pursuing a digital transformation and AI-driven strategy. At $51.92, SLB trades at 2.18x P/S (in the fair range of the 5-year di…
Accumulation Zones
| Metric |
JNJ |
SLB |
| Zone Low |
$157.71 |
$34.00 |
| Zone High |
$178.74 |
$39.00 |
| In Buy Zone? |
No
|
No
|